Insider trade

Officer received an award of 784 CME shares

Traded Sep 15, 2026 · Filed Sep 17, 2026

CME GroupCME

784
Shares · @ $275.09

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Sep 15, 2026
Reporting period: Not applicable
Filed with the SEC: Sep 17, 2026

OfficerGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0002153052-26-000002
Filed / recorded

Sep 17, 2026, 8:23 PM UTC

Added to OQRO

Oct 2, 2026, 12:27 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

CME GROUP INC.

Issuer CIK

1156375

Ticker

CME

Reporting person

John Clifford Marchese

Relationship

Officer

Officer title

Sr MD, General Counsel

Security

Common Stock Class A

Table

Non-derivative (Table I)

Transaction date

Sep 15, 2026

Transaction code

A

Shares / units

784

Price per share

$275.09

Acquired / disposed

Acquired (A)

Shares owned after

3,839

Ownership form

Direct

Amendment

No

Footnotes from the filing

Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service. This grant was determined based on the Reporting Person's role as of September 1, 2026 and prior to the effective date of his promotion to Senior Managing Director and General Counsel on September 11, 2026. Under CME Group's compensation program, the Reporting Person is entitled to a promotion-related equity grant in March 2027, which would be reported on a subsequent Form 4.